{
    "nct_id": "NCT04692675",
    "official_title": "Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n* Participants must have confirmed histopathological diagnosis of adenocarcinoma of the prostate within 2 years prior to study entry. Pathologic diagnosis must be confirmed by Laboratory of Pathology, NCI. If archival tissue is unavailable or insufficient for this purpose, a fresh biopsy will be collected.\n* Biopsy confirmed prostate cancer with Gleason less than or equal to 3+4=7 (primary pattern 3)\n* Clinical stage: cT1C or cT2A\n* Adult males, greater than or equal to 18 years old\n\nNOTE: Children are excluded because prostate cancer is not common in pediatric populations. Women are not eligible because this disease occurs only in men.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document All participants should have a consent signed that demonstrates an understanding of active surveillance and the decision to choose active surveillance for their prostate cancer.\n* Subjects must be co-enrolled to NCI protocol 16-C-0010 Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue\n\nEXCLUSION CRITERIA:\n\n* Metastatic prostate cancer/locally advanced disease\n* Previous radiation to the pelvis\n* Contraindications to prostate biopsy, including:\n\n  * Bleeding disorder that is not currently treated and stable with normal INR values greater than 2 and PT, PTT less than or equal to 1.5 times the upper limit of normal value.\n  * Severe immunocompromise with CD4 count of less than 200 in HIV patients and bone marrow transplantation patients and or patients with severe combined immunodeficiency.\n  * Severe hemorrhoids grade 3 and above\n  * Prior surgery in the pelvis that prevents accurate imaging or biopsy including low anterior resection or abdominoperineal resection.\n  * Prior focal or whole gland therapy of the prostate for prostate cancer\n* Contraindication to mpMRI, including allergy or sensitivity to contrast agents or insufficient renal function to safely tolerate MRI contrast agent\n* mpMRI evidence of greater than or equal to T3 disease, including seminal vesicle invasion (SVI), extraprostatic extension (EPE) or locoregional spread of disease\n* Any other medical conditions deemed by the PI or associates to make the participants ineligible for protocol procedures\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}